Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells.

1-beta-d-Arabinofuranosylcytosine (Ara-C) is a nucleoside analog commonly used in the treatment of leukemias. Ara-C inhibits DNA polymerases and can be incorporated into DNA. Its mechanism of cytotoxicity is not fully understood. Using oligonucleotides and purified human topoisomerase I (top1), we found a 4- to 6-fold enhancement of top1 cleavage complexes when ara-C was incorporated at the +1 position (immediately 3') relative to a unique top1 cleavage site. This enhancement was primarily due to a reversible inhibition of top1-mediated DNA religation. Because ara-C incorporation is known to alter base stacking and sugar puckering at the misincorporation site and at the neighboring base pairs, the observed inhibition of religation at the ara-C site suggests the importance of the alignment of the 5'-hydroxyl end for religation with the phosphate group of the top1 phosphotyrosine bond. This study also demonstrates that ara-C treatment and DNA incorporation trap top1 cleavage complexes in human leukemia cells. Finally, we report that camptothecin-resistant mouse P388/CPT45 cells with no detectable top1 are crossresistant to ara-C, which suggests that top1 poisoning is a potential mechanism for ara-C cytotoxicity.

[1]  Y. Pommier,et al.  Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Y. Pommier,et al.  Induction of Reversible Complexes between Eukaryotic DNA Topoisomerase I and DNA-containing Oxidative Base Damages , 1999, The Journal of Biological Chemistry.

[3]  Y. Pommier,et al.  Induction of Topoisomerase I Cleavage Complexes by the Vinyl Chloride Adduct 1,N 6-Ethenoadenine* , 1998, The Journal of Biological Chemistry.

[4]  Y. Pommier,et al.  Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. , 1998, Biochimica et biophysica acta.

[5]  J N Weinstein,et al.  Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. , 1998, Journal of medicinal chemistry.

[6]  W G Hol,et al.  A model for the mechanism of human topoisomerase I. , 1998, Science.

[7]  J. Champoux,et al.  Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. , 1998, Science.

[8]  S. Grant,et al.  Ara-C: cellular and molecular pharmacology. , 1998, Advances in cancer research.

[9]  Y. Pommier,et al.  Trapping of Mammalian Topoisomerase I and Recombinations Induced by Damaged DNA Containing Nicks or Gaps , 1997, The Journal of Biological Chemistry.

[10]  Y. Pommier,et al.  Aclacinomycin A stabilizes topoisomerase I covalent complexes. , 1997, Cancer research.

[11]  K. Kohn,et al.  Effects of Uracil Incorporation, DNA Mismatches, and Abasic Sites on Cleavage and Religation Activities of Mammalian Topoisomerase I* , 1997, The Journal of Biological Chemistry.

[12]  S. Morham,et al.  Targeted disruption of the mouse topoisomerase I gene by camptothecin selection , 1996, Molecular and cellular biology.

[13]  G. Ireton,et al.  Biochemical and Biophysical Analyses of Recombinant Forms of Human Topoisomerase I (*) , 1996, The Journal of Biological Chemistry.

[14]  S. Tornaletti,et al.  Human DNA Topoisomerase I-mediated Cleavages Stimulated by Ultraviolet Light-induced DNA Damage (*) , 1996, The Journal of Biological Chemistry.

[15]  Y. Pommier,et al.  Eukaryotic DNA topoisomerases I. , 1995, Biochimica et biophysica acta.

[16]  E. Kraut,et al.  Analysis of topoisomerase I/DNA complexes in patients administered topotecan. , 1995, Cancer research.

[17]  K. Gardner,et al.  Solution structure of a DNA dodecamer containing the anti-neoplastic agent arabinosylcytosine: combined use of NMR, restrained molecular dynamics, and full relaxation matrix refinement. , 1994, Biochemistry.

[18]  C. Moore,et al.  Overexpression of human DNA topoisomerase I in insect cells using a baculovirus vector. , 1994, Protein expression and purification.

[19]  A. Lu,et al.  Mammalian topoisomerase I has base mismatch nicking activity. , 1994, The Journal of biological chemistry.

[20]  K W Kohn,et al.  Mechanisms of topoisomerase I inhibition by anticancer drugs. , 1994, Advances in pharmacology.

[21]  A. Andersen,et al.  Eukaryotic topoisomerase I-mediated cleavage requires bipartite DNA interaction. Cleavage of DNA substrates containing strand interruptions implicates a role for topoisomerase I in illegitimate recombination. , 1993, The Journal of biological chemistry.

[22]  G. Hofmann,et al.  In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. , 1993, Oncology research.

[23]  S. Shuman.  Two classes of DNA end-joining reactions catalyzed by vaccinia topoisomerase I. , 1992, The Journal of biological chemistry.

[24]  J. Svejstrup,et al.  New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site. , 1991, Journal of molecular biology.

[25]  G. Hofmann,et al.  Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). , 1991, Cancer research.

[26]  G. A. van der Marel,et al.  Molecular structure of a DNA decamber containing an anticancer nucleoside arabinosylcytosine: conformational perturbation by arabinosylcytosine in B-DNA. , 1991, Biochemistry.

[27]  J. Champoux.  6 Mechanistic Aspects of Type-I Topoisomerases , 1990 .

[28]  O. Westergaard,et al.  A high affinity topoisomerase I binding sequence is clustered at DNAase I hypersensitive sites in tetrahymena R-chromatin , 1985, Cell.

[29]  D. Kufe,et al.  Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. , 1984, Blood.

[30]  J. Champoux.  DNA is linked to the rat liver DNA nicking-closing enzyme by a phosphodiester bond to tyrosine. , 1981, The Journal of biological chemistry.

[31]  D. Kufe,et al.  Correlation of cytotoxicity with incorporation of ara-C into DNA. , 1980, The Journal of biological chemistry.

[32]  J. Regan,et al.  Inhibition of DNA excision repair in human cells by arabinofuranosyl cytosine: effect on normal and xeroderma pigmentosum cells. , 1979, Molecular pharmacology.

[33]  S. Yoshida,et al.  Inhibition of DNA polymerase-α and -β of calf thymus by 1-β-d-arabinofuranosylcytosine-5′-triphosphate , 1977 .

[34]  N. Cozzarelli.  The mechanism of action of inhibitors of DNA synthesis. , 1977, Annual review of biochemistry.

[35]  G. Mueller,et al.  Simple procedure for isolation of DNA, RNA and protein fractions from cultured animal cells. , 1975, Analytical biochemistry.

[36]  F. Graham,et al.  The Effect of 1-β-d-Arabinofuranosylcytosine on Growth, Viability, and DNA Synthesis of Mouse L-cells , 1970 .

[37]  J. Furth,et al.  Inhibition of Mammalian DNA Polymerase by the 5′-Triphosphate of 1-β-d-Arabinofuranosylcytosine and the 5′-Triphosphate of 9-β-d-Arabinofuranosyladenine , 1968 .